MBX Biosciences' Canvuparatide Shows Sustained One-Year Benefit in Hypoparathyroidism, Phase 3 On Track
MBX has more than doubled off its 52-week low of $9.43 on elevated volume (4.5× avg).
Summary
MBX Biosciences announced positive one-year data from the open-label extension of its Phase 2 trial for canvuparatide in chronic hypoparathyroidism. The drug showed sustained benefit with a 57% responder rate at one year, consistent with earlier Phase 2 results, and no new safety signals. This strong data, coupled with a 90% patient retention rate, significantly de-risks the asset. The company remains on track to initiate the pivotal Phase 3 trial in Q3 2026.
At the time of this announcement, MBX was trading at $35.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $9.43 to $45.85. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.